Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting
-
Dodgers beat Braves to advance in MLB playoffs, Rays oust Yankees
-
The growing protests against India's poll body - and PM Modi
-
'A sun as black as my lungs': how corruption crucified a polluted Albania city
-
Stocks fall further as oil spike fans fresh inflation worries
-
The British historian helping the French rediscover de Gaulle
-
Bad COP, worse COP? EU tempers hopes for UN climate summit
-
Dodgers beat Braves to advance, Guardians survive in MLB playoffs
-
Rookie Henry named in Wallabies midfield to face All Blacks
-
Latin American, Caribbean women top Nobel literature buzz
-
Housing crisis set to dominate Spain's snap election
-
US says Fiji-based Chinese official paid bribes for Beijing
-
Gas, health care, utilities: high costs squeeze US midterm voters
-
After botched US execution, Christa Pike was nearly taken off life support
-
New Zealand Rugby seeks injunction over PNG Chiefs name
-
Guinea-Bissau junta urges military unit loyal to ex-president to disarm
-
Samsung expects 780% quarterly operating profit jump on AI boom
-
As species decline, green turtles offer glimmer of hope
-
Guardians survive with 9-3 win over White Sox
-
Brothers Scott and Beauden Barrett named to start for All Blacks
-
Saudi Arabia says 3 dead at airports after Houthis claim attacks
-
EU trade chief seeks to dial down China tensions
-
Stocks slide as oil sees volatile trading day over Iran war fears
-
'Never again Bolsonaro': thousands march ahead of Brazil election runoff
-
Microsoft pushes AI vision with new, expensive Surface laptop
-
After botched execution, US woman was nearly taken off life support before revival
-
Five children among 28 killed in Russian strikes on Ukraine
-
Searing AIDS drama 'Elsinore' opens London film festival
-
Odell Beckham Jr signs with Minnesota Vikings
-
Evicted pensioner who sparked Spain housing protests dies: tenant union
-
Saudi Arabia says three dead at airports after Houthis claim attacks
-
Golf star Rahm quitting LIV tour over 'unacceptable' terms
-
Trump plans to turn Florida golf course into presidential retreat
-
Thousands march fearing return of a Bolsonaro presidency in Brazil
-
WHO says cannot conduct full risk assessment on Russia plague reports
-
French PM denies police ordered to confront student protesters
-
After botched execution, US woman is awake and shackled to bed
-
Rubio touts US power, calls on Europe to emerge from 'slumber'
-
New Zealand fly-half Mo'unga ruled out of Australia Tests
-
Trump says 'we don't think' Russian plague is bio-weapon
-
Protests in major Turkish city after mayor defects to Erdogan party
-
Five children among 26 killed in Ukraine after Russian strikes
-
Climate change strips island's title of largest penguin colony: study
-
Man City should 'accept' punishment for rule breaches, says Lineker
-
Rubio says West must choose between national power or decline
-
US woman who survived botched execution is awake and speaking
-
Russia's plague scare: What we know
-
From 1800s to modern pharma: a Nobel-winning chemistry quest
-
French luxury giant to fund redevelopment of two Paris streets: city hall
-
Southampton boss Eckert given suspended ban over 'Spygate'
-
Trump wants to turn Florida golf course into presidential retreat
Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting
FRAMINGHAM, MA / ACCESS Newswire / April 22, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its abstract has been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 - June 2, 2026, in Chicago, IL.
The accepted abstract, titled "Targeting cfDNA and NETs with DNase I to augment CAR T cell function and antitumor efficacy," highlights preclinical research supporting Xenetic's DNase-based therapeutic approach designed to enhance CAR T-cell activity and improve antitumor responses.
Presentation Details:
Session Title: Hematologic Malignancies - Plasma Cell Dyscrasia (Poster Session)
Abstract Title: Targeting cfDNA and NETs with DNase I to augment CAR T cell function and antitumor efficacy
Poster Board: 410
Presentation Date & Time: June 1, 2026, 9:00 AM - 12:00 PM CDT
Presenter: Alexey V. Stepanov, PhD
The poster will be available to conference attendees during the scheduled session. For more information, please visit asco.org.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's proprietary DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.
CONTACT:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
[email protected]
SOURCE: Xenetic Biosciences, Inc.
View the original press release on ACCESS Newswire
H.Romero--AT
